A disruptive technology to tackle brain cancer and glioblastoma
News
Hemerion’s breakthrough glioblastoma approach featured in new peer-reviewed case report
A newly published case report in the renowned Journal of Neuro-Oncology Discovery provides compelling clinical evidence of the feasibility, safety and workflow integration of the Pentalafen®/Heliance® combination therapy in treating… ...
Hemerion launches a Sponsored Clinical Studies program
The program supports investigator-sponsored clinical studies (ISS) or investigator-initiated trials (IIT). Our goal: to offer researchers and clinicians the opportunity to explore new indications, expand the use of Pentalafen®/Heliance® combination… ...
International development: Hemerion wins the LeadExport Trophy
The Hauts-de-France Chamber of Commerce and Industry awarded Hemerion the LeadExport Trophy in the Innovation category in recognition of its international activities. This award recognises Hemerion's efforts to accelerate the… ...
Stay tuned to our clinical advances
They talk about us
